Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

A Multi-center, Phase 2 Study for Autologous T Cells Transfected With mRNA Encoding HBV Antigen-specific TCR (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for Advanced HBV-related Hepatocellular Carcinoma

This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).

Study Overview

• Status: Not yet recruiting
• Conditions: Hepatocellular Carcinoma; Liver Cell Carcinoma; Liver Cancer, Adult
• Intervention / Treatment: Biological: LioCyx-M; Drug: Lenvatinib

• Study Type: Interventional
• Enrollment (Estimated): 55
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Regina Wong; Phone Number: +65 68130738; Email: regina.wong@liontcr.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
2. Advanced HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD criteria in cirrhotic patients.
3. Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
4. Patients who failed first-line systemic therapy for HCC
5. Serum HBsAg positivity
6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)
7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor

Exclusion Criteria:

1. Brain metastasis
2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours.
3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples
4. History of severe allergic anaphylactic reactions to T cell therapy products and/or lenvatinib
5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first infusion of LioCyx-M.
6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy.
7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis.
8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed)
10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV)
11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina
12. Uncontrolled hypertension, defined as systolic blood pressure >160 mmHg or diastolic pressure >110 mmHg, despite optimal medical management

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LioCyx-M monotherapy; Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M).	Biological: LioCyx-M; HBV antigen specific TCR redirected T cells
Experimental: LioCyx-M + lenvatinib combinational therapy; Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M) with daily intake of lenvatinib.	Biological: LioCyx-M; HBV antigen specific TCR redirected T cells; Drug: Lenvatinib; 12 mg once daily for patients ≥60 kg, 8 mg for patients <60kg by oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessments of adverse events/serious adverse events	To evaluate the safety of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Objective response rate (ORR)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival (PFS)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Time to radiographic progression (TTRP)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Duration of response (DoR)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation
Overall survival (OS)	To evaluate the anti-tumor efficacy of LioCyx-M as a monotherapy and in combination with lenvatinib	Up to 4 years from study treatment initiation

Collaborators and Investigators

• Sponsor: Lion TCR Pte. Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: June 3, 2021
• First Submitted That Met QC Criteria: January 4, 2022
• First Posted (Actual): January 18, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 5, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Hepatocellular Carcinoma; HBV; Hepatitis B virus; TCR T cells
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Digestive System Neoplasms; Digestive System Diseases; Liver Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Lenvatinib
• Other Study ID Numbers: LTCR-HCC-3-4

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No